• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

清髓性和非清髓性预处理患者接受异基因造血干细胞移植后的功能性免疫重建

Functional immune reconstitution after allogeneic hematopoietic stem cell transplantation in myeloablative and non-myeloablative conditioned patients.

作者信息

Brooks Patrick Terrence, Minculescu Lia, Svanberg Teglgaard Rebecca, Hartling Hans Jakob, Salado-Jimena Jose Antonio, Friis Lone Smidstrup, Kornblit Brian, Schjødt Ida, Petersen Søren Lykke, Andersen Niels Smedegaard, Nielsen Susanne Dam, Lundgren Jens, Marquart Hanne Vibeke, Gjaerde Lars Klingen, Sengeløv Henrik, Ostrowski Sisse Rye

机构信息

Department of Clinical Immunology, Copenhagen University Hospital, Rigshospitalet Inge Lehmanns Vej 7, Copenhagen, 2100, Denmark.

Department of Hematology, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark.

出版信息

Sci Rep. 2025 Jul 1;15(1):21029. doi: 10.1038/s41598-025-06718-y.

DOI:10.1038/s41598-025-06718-y
PMID:40595122
Abstract

Allogeneic hematopoietic stem cell transplantation (allo-HCT) is a treatment modality for several hematological and immune-driven diseases. A conditioning regimen precedes transplantation. These comprise myeloablative (MA) conditioning consisting of chemotherapeutics often in combination with high-dose total body irradiation (TBI), while non-myeloablative (NMA) conditioning regimens use reduced dosage of chemotherapy and TBI allowing allo-HCT to patients who would otherwise not be eligible for treatment. While cellular immune reconstitution in allo-HCT patients has been well studied, differences between MA and NMA conditioned patients including the functional status of the immune system post-transplantation remains unclear. Seventy-seven patients undergoing allo-HCT were included in the main study, only including patients receiving peripheral blood stem cell grafts, no ATG treatment and no other GVHD prophylaxis than tacrolimus + methotrexate or cyclosporine + MMF + sirolimus (median age 59; IQR: 48-65). The cohort consisted of 34 patients receiving MA conditioning and 43 NMA conditioned patients. As a proxy for post-transplantation immune function, we analyzed stimulated cytokine release patterns in whole-blood samples from MA and NMA patients before and after transplantation alongside major immune cell phenotypes and T cell chimerism on day 28 after transplantation. Notably, among patients receiving grafts from peripheral blood apheresis, MA patients exhibited higher T cell counts, and elevated CD3/CD28-stimulated cytokine release compared to NMA patients. Assessment of associations between cytokine release and immune cell concentration associations indicated that variation in T cell or other immune cell concentrations between the cohorts could not account for differences in CD3/CD28-stimulated cytokine release. Meanwhile, LPS- and R848-stimulated cytokine release was associated with innate immune cell subtypes. A secondary study amongst MA conditioned patients further revealed that those who received fludarabine and treosulfan (n = 35) had higher T cell concentration and stimulated immune function compared to patients receiving more intense MA regimens (n = 15). These findings highlight the complex impact conditioning has on immune function after allo-HCT. Further analyses of T cell compartments and myeloid/lymphoid innate cells are needed to further understand the functional differences observed between conditioning groups and the potential impact on clinical outcomes.

摘要

异基因造血干细胞移植(allo-HCT)是治疗多种血液系统疾病和免疫相关疾病的一种治疗方式。移植前需进行预处理方案。这些方案包括清髓性(MA)预处理,通常由化疗药物联合大剂量全身照射(TBI)组成,而非清髓性(NMA)预处理方案使用剂量降低的化疗和TBI,使allo-HCT能够应用于那些原本不符合治疗条件的患者。虽然对allo-HCT患者的细胞免疫重建已进行了充分研究,但MA和NMA预处理患者之间的差异,包括移植后免疫系统的功能状态仍不清楚。主要研究纳入了77例接受allo-HCT的患者,仅包括接受外周血干细胞移植、未接受抗胸腺细胞球蛋白(ATG)治疗且除他克莫司+甲氨蝶呤或环孢素+霉酚酸酯+西罗莫司外未接受其他移植物抗宿主病(GVHD)预防措施的患者(中位年龄59岁;四分位间距:48 - 65岁)。该队列包括34例接受MA预处理的患者和43例接受NMA预处理的患者。作为移植后免疫功能的替代指标,我们分析了MA和NMA患者移植前后全血样本中刺激后的细胞因子释放模式,以及移植后第28天的主要免疫细胞表型和T细胞嵌合情况。值得注意的是,在接受外周血单采移植的患者中,MA患者的T细胞计数更高,且与NMA患者相比,CD3/CD28刺激后的细胞因子释放升高。对细胞因子释放与免疫细胞浓度关联的评估表明,队列间T细胞或其他免疫细胞浓度的差异无法解释CD3/CD28刺激后的细胞因子释放差异。同时,脂多糖(LPS)和R848刺激后的细胞因子释放与固有免疫细胞亚型相关。对MA预处理患者的一项二次研究进一步显示,与接受更强化MA方案的患者(n = 15)相比,接受氟达拉滨和曲奥舒凡的患者(n = 35)T细胞浓度更高且免疫功能受刺激更强。这些发现突出了预处理对allo-HCT后免疫功能的复杂影响。需要进一步分析T细胞亚群以及髓系/淋巴系固有细胞,以进一步了解预处理组之间观察到的功能差异以及对临床结局的潜在影响。

相似文献

1
Functional immune reconstitution after allogeneic hematopoietic stem cell transplantation in myeloablative and non-myeloablative conditioned patients.清髓性和非清髓性预处理患者接受异基因造血干细胞移植后的功能性免疫重建
Sci Rep. 2025 Jul 1;15(1):21029. doi: 10.1038/s41598-025-06718-y.
2
The Incidence and Severity of Oral Mucositis among Allogeneic Hematopoietic Stem Cell Transplantation Patients: A Systematic Review.异基因造血干细胞移植患者口腔黏膜炎的发病率和严重程度:一项系统评价
Biol Blood Marrow Transplant. 2016 Apr;22(4):605-616. doi: 10.1016/j.bbmt.2015.09.014. Epub 2015 Sep 26.
3
Polyclonal anti-thymocyte globulins for the prophylaxis of graft-versus-host disease after allogeneic stem cell or bone marrow transplantation in adults.用于预防成人异基因干细胞或骨髓移植后移植物抗宿主病的多克隆抗胸腺细胞球蛋白。
Cochrane Database Syst Rev. 2023 Jun 21;6(6):CD009159. doi: 10.1002/14651858.CD009159.pub3.
4
Treatment-Responsive Acute Graft-versus-Host Disease after Post-Transplantation Cyclophosphamide-Based Prophylaxis: Incidence and Clinical Outcomes.移植后环磷酰胺预防治疗后发生的治疗反应性急性移植物抗宿主病:发生率和临床结局。
Transplant Cell Ther. 2024 Jul;30(7):688.e1-688.e9. doi: 10.1016/j.jtct.2024.05.007. Epub 2024 May 9.
5
Polyclonal anti-thymocyte globulins for the prophylaxis of graft-versus-host disease after allogeneic stem cell or bone marrow transplantation in adults.多克隆抗胸腺细胞球蛋白用于预防成人异基因干细胞或骨髓移植后的移植物抗宿主病。
Cochrane Database Syst Rev. 2012 Sep 12(9):CD009159. doi: 10.1002/14651858.CD009159.pub2.
6
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.系统性药理学治疗慢性斑块状银屑病:网络荟萃分析。
Cochrane Database Syst Rev. 2021 Apr 19;4(4):CD011535. doi: 10.1002/14651858.CD011535.pub4.
7
Allogeneic hematopoietic cell transplantation for adult acute lymphoblastic leukemia (ALL) in first complete remission.异基因造血细胞移植用于首次完全缓解的成人急性淋巴细胞白血病(ALL)。
Cochrane Database Syst Rev. 2011 Oct 5;2011(10):CD008818. doi: 10.1002/14651858.CD008818.pub2.
8
Periodontal changes after haematopoietic cell transplantation and the role of conditioning regimen intensity.造血细胞移植后的牙周变化及预处理方案强度的作用。
Support Care Cancer. 2025 Jun 23;33(7):612. doi: 10.1007/s00520-025-09654-9.
9
Upfront Haploidentical Hematopoietic Cell Transplantation Using αβ T Cell-Depleted Peripheral Blood Stem Cells for Pediatric Patients with Acquired Severe Aplastic Anemia.使用αβ T细胞去除的外周血干细胞对获得性重型再生障碍性贫血患儿进行一线单倍体相合造血细胞移植
Transplant Cell Ther. 2025 Jun 10. doi: 10.1016/j.jtct.2025.06.012.
10
Does Augmenting Irradiated Autografts With Free Vascularized Fibula Graft in Patients With Bone Loss From a Malignant Tumor Achieve Union, Function, and Complication Rate Comparably to Patients Without Bone Loss and Augmentation When Reconstructing Intercalary Resections in the Lower Extremity?对于因恶性肿瘤导致骨缺损的患者,在重建下肢节段性切除时,采用带血管游离腓骨移植来增强照射后的自体骨移植,其骨愈合、功能及并发症发生率与无骨缺损且未进行增强的患者相比是否相当?
Clin Orthop Relat Res. 2025 Jun 26. doi: 10.1097/CORR.0000000000003599.

本文引用的文献

1
Outcomes of Antithymocyte Globulin-Post-Transplantation Cyclophosphamide-Cyclosporine-Based versus Antithymocyte Globulin-Based Prophylaxis for 10/10 HLA-Matched Unrelated Donor Allogeneic Hematopoietic Cell Transplantation.抗胸腺细胞球蛋白移植后环磷酰胺-环孢素与抗胸腺细胞球蛋白预防 10/10 HLA 匹配非亲缘供体异基因造血细胞移植的结果。
Transplant Cell Ther. 2024 May;30(5):536.e1-536.e13. doi: 10.1016/j.jtct.2024.01.075. Epub 2024 Jan 27.
2
The remission status of AML patients after allo-HCT is associated with a distinct single-cell bone marrow T-cell signature.异基因造血干细胞移植后 AML 患者的缓解状态与独特的骨髓单个核细胞 T 细胞特征有关。
Blood. 2024 Mar 28;143(13):1269-1281. doi: 10.1182/blood.2023021815.
3
Early immune reconstitution as predictor for outcomes after allogeneic hematopoietic cell transplant; a tri-institutional analysis.
异基因造血细胞移植后早期免疫重建预测结果:一项三机构分析。
Cytotherapy. 2023 Sep;25(9):977-985. doi: 10.1016/j.jcyt.2023.05.012. Epub 2023 Jun 16.
4
Immunosenescence: molecular mechanisms and diseases.免疫衰老:分子机制与疾病。
Signal Transduct Target Ther. 2023 May 13;8(1):200. doi: 10.1038/s41392-023-01451-2.
5
Oxidative DNA damage in reconstituting T cells is associated with relapse and inferior survival after allo-SCT.重建T细胞中的氧化性DNA损伤与异基因造血干细胞移植后的复发及较差的生存率相关。
Blood. 2023 Mar 30;141(13):1626-1639. doi: 10.1182/blood.2022017267.
6
Impact of natural killer cells on outcomes after allogeneic hematopoietic stem cell transplantation: A systematic review and meta-analysis.自然杀伤细胞对异基因造血干细胞移植后结局的影响:系统评价和荟萃分析。
Front Immunol. 2022 Oct 3;13:1005031. doi: 10.3389/fimmu.2022.1005031. eCollection 2022.
7
Early stimulated immune responses predict clinical disease severity in hospitalized COVID-19 patients.早期激发的免疫反应可预测住院COVID-19患者的临床疾病严重程度。
Commun Med (Lond). 2022 Sep 12;2:114. doi: 10.1038/s43856-022-00178-5. eCollection 2022.
8
An ISCT Stem Cell Engineering Committee Position Statement on Immune Reconstitution: the importance of predictable and modifiable milestones of immune reconstitution to transplant outcomes.国际细胞治疗学会干细胞工程委员会关于免疫重建的立场声明:免疫重建可预测且可改变的里程碑对移植结果的重要性。
Cytotherapy. 2022 Apr;24(4):385-392. doi: 10.1016/j.jcyt.2021.09.011.
9
Do antibiotics cause mitochondrial and immune cell dysfunction? A literature review.抗生素会导致线粒体和免疫细胞功能障碍吗?文献综述。
J Antimicrob Chemother. 2022 Apr 27;77(5):1218-1227. doi: 10.1093/jac/dkac025.
10
Immune Reconstitution After Allogeneic Haematopoietic Cell Transplantation: From Observational Studies to Targeted Interventions.异基因造血细胞移植后的免疫重建:从观察性研究到靶向干预
Front Pediatr. 2022 Jan 11;9:786017. doi: 10.3389/fped.2021.786017. eCollection 2021.